eNews
eNews: Claimsecure’s NEW website
Dear Valued Clients, We are excited to announce ClaimSecure’s NEW website will be launched on Thursday August 24th, 2023. We have listened to your feedback
eNews: MOVEit vulnerability.
Dear Valued Clients, In late May, it came to light that “MOVEit transfer”, a software used to provide file transfer services, had a vulnerability that
TEZSPIRE® – A New Treatment Option for Severe Asthma
Drug Review: Volume 23, Issue 7 (PDF) Asthma is a chronic lung disease characterized by wheezing, shortness of breath, cough and chesttightness. Approximately 2.4 million Canadians
UBRELVY® – A First-In-Class Therapy for the Treatment of Migraines
Drug Review: Volume 23, Issue 6 (PDF) Migraines are a class of debilitating headaches that reduce patients’ quality of life, work performance and productivity. It
VRAYLAR® – A New Treatment Option for Schizophrenia & Bipolar I Disorder
Drug Review: Volume 23, Issue 5 (PDF) Schizophrenia is a mental disorder characterized by a range of symptoms including psychosis (hallucinations, delusions, and hyperactivity), reduced motivation,
KORSUVA® – First Approved Drug for Chronic Kidney Disease-associated Pruritis
Drug Review: Volume 23, Issue 4 (PDF) Chronic Kidney Disease (CKD) is the gradual and irreversible loss of kidney function over several months to years. Chronic
Novel Treatment Options for Insomnia
Drug Review: Volume 23, Issue 3 (PDF) Insomnia is a sleep disorder that is characterized by symptoms of difficulty initiating sleep, difficulty maintaining sleep, or early-morning
KERENDIA® – A New Treatment for Chronic Kidney Disease Associated with Diabetes
Drug Review: Volume 23, Issue 2 (PDF) Chronic Kidney Disease (CKD) is the gradual and irreversible loss of kidney function over several months to years. The
VABYSMO® – A New Treatment for Chronic Eye Conditions Related to Macular Edema
Drug Review: Volume 23, Issue 1 (PDF) The macula is the part of the eye responsible for sharp, clear central vision. Macular edema occurs when the